Biogen Inc
NASDAQ: BIIB
$199.36
-$2.08 (-1.0%)
Closing Price on September 20, 2024
BIIB Articles
The short interest data are out for the August 14 settlement date. Biotech companies are considered a riskier group of stocks.
Published:
Applied Genetic Technologies announced that the Biogen equity investment as part of their collaboration has closed.
Published:
The short interest data are out for the July 31 settlement date, and overall, short interest in the selected biotech stocks backed off for this period.
Published:
It may be impossible to ever know if a true bottom has ever been seen, but many investors love finding great companies where they feel that a sell-off has overly punished the share price.
Published:
Tuesday's top analyst upgrades, downgrades and initiations include Adobe, Biogen, Google, PDC Energy, Rackspace and XL Group.
Published:
Merrill Lynch has looked at large cap biotech leaders and how interest rate increases may play a part in stock performance.
Published:
ThinkstockThere are times when a negative piece of news in the BioPharma sector can actually help rival companies. Biogen Inc. (NASDAQ: BIIB) is a stock that has been battered of late, and it is a...
Published:
In a new research report, Cowen's well-respected analyst Ken Cacciatore makes a very good case that some huge, high-profile biotech companies could be targeted for buyouts.
Published:
ThinkstockNothing like earnings season coming around to buy stock if you are an insider and your company happens to disappoint. While most of the S&P 500 companies have reported as August begins,...
Published:
Jon OggStocks were indicated lower by almost 1% on Monday after China’s Shanghai market suffered its biggest loss in about 8 years on Monday. The one trend that has held up for almost 4 years now...
Published:
ThinkstockThe short interest data are out for the July 15 settlement date. Biotech companies are considered a riskier group of stocks, with big upside and big downside. FDA rulings can make or break...
Published:
Last Updated:
ThinkstockPharmaceutical and Biotech investors are about to get a real show for earnings this week. Big Pharma will bring earnings from Dow Jones Industrial Average companies Merck & Co. Inc....
Published:
Biogen reported mixed second-quarter 2015 results before markets opened Friday morning.
Published:
Last Updated:
Biogen is scheduled to release its second-quarter financial results before the markets open on Friday.
Published:
It seems Biogen's closely watched Alzheimer's drug candidate, aducanumab, has fallen short of analyst and investor expectations.
Published: